Oxytocin
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Oxytocin
- Generic name
- OXYTOCIN
- Manufacturer
- West-Ward Pharmaceuticals Corp
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- d16a48c5-6b71-40a0-bcda-204f043fe832
- SPL ID
- 9a99920c-c630-487a-a1fc-5289eeaf451b
- Version
- 2
- Effective date
- 2018-12-14
- Source export date
- 2026-10-12
- Source partition
- 6
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/b25dad4aaef9c88f0e827394a34fbbd1ce7d71422fa46b5d1e123befad498c1d/drug-label-0006-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 01:46:04
| Harmonized routes |
|---|
| INTRAMUSCULAR, INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 200219 | derived:openfda.application_number |
| application number | ANDA200219 | openfda.application_number | |
| brand name | Oxytocin | openfda.brand_name | |
| generic name | OXYTOCIN | openfda.generic_name | |
| manufacturer name | West-Ward Pharmaceuticals Corp | openfda.manufacturer_name | |
| ndc | package | 0143-9742-01 | openfda.package_ndc |
| ndc | package | 0143-9743-25 | openfda.package_ndc |
| ndc | package | 0143-9743-01 | openfda.package_ndc |
| ndc | package | 0143-9742-25 | openfda.package_ndc |
| ndc | product | 0143-9743 | openfda.product_ndc |
| ndc | product | 0143-9742 | openfda.product_ndc |
| ndc11 | package | 00143974225 | derived:openfda.package_ndc |
| ndc11 | package | 00143974301 | derived:openfda.package_ndc |
| ndc11 | package | 00143974201 | derived:openfda.package_ndc |
| ndc11 | package | 00143974325 | derived:openfda.package_ndc |
| rxcui | 1791721 | openfda.rxcui | |
| rxcui | 238013 | openfda.rxcui | |
| spl id | 9a99920c-c630-487a-a1fc-5289eeaf451b | id | |
| spl set id | d16a48c5-6b71-40a0-bcda-204f043fe832 | set_id | |
| unii | 1JQS135EYN | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
IMPORTANT NOTICE Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
WARNINGS Oxytocin injection (synthetic) when given for induction or stimulation of labor, must be administered only by the intravenous route, and with adequate medical supervision in a hospital.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS The following adverse reactions have been reported in the mother: Anaphylactic reaction Nausea Postpartum hemorrhage Vomiting Cardiac arrhythmia Premature ventricular contractions Fatal afibrinogenemia Pelvic hematoma Excessive dosage or hypersensitivity to the drug may result in uterine hypertonicity, spasm, tetanic contraction or rupture of the uterus. The possibility of increased blood loss and afibrinogenemia should be kept in mind when administering the drug. Severe water intoxication with convulsions and coma has occurred, and is associated with a slow oxytocin infusion over a 24-hour period. Maternal death due to oxytocin-induced water intoxication has been reported. The following adverse reactions have been reported in the fetus or infant: Due to induced uterine mobility Due to use of oxytocin in the mother Bradycardia Neonatal retinal hemorrhage Premature ventricular contractions and other arrhythmias Low Apgar scores at five minutes Permanent CNS or brain damage Neonatal jaundice Fetal death
adverse reactions table
<table> <col/> <col/> <tbody> <tr> <td> Anaphylactic reaction </td> <td> Nausea </td> </tr> <tr> <td> Postpartum hemorrhage</td> <td> Vomiting</td> </tr> <tr> <td> Cardiac arrhythmia</td> <td> Premature ventricular contractions</td> </tr> <tr> <td> Fatal afibrinogenemia</td> <td> Pelvic hematoma</td> </tr> </tbody> </table>
adverse reactions table
<table> <col/> <col/> <tbody> <tr> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold"> <content styleCode="italics">Due to induced uterine mobility</content> </content> </td> <td styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold"> <content styleCode="italics"> Due to use of oxytocin in the mother</content> </content> </td> </tr> <tr> <td styleCode=" Lrule Rrule "> Bradycardia</td> <td styleCode=" Lrule Rrule "> Neonatal retinal hemorrhage</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Premature ventricular contractions and other arrhythmias</td> <td styleCode=" Lrule Rrule "> Low Apgar scores at five minutes</td> </tr> <tr> <td styleCode=" Lrule Rrule "> Permanent CNS or brain damage</td> <td styleCode=" Lrule Rrule "> Neonatal jaundice</td> </tr> <tr> <td styleCode=" Botrule Lrule Rrule "> Fetal death</td> <td styleCode=" Botrule Lrule Rrule "> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.